OncoMatch/Clinical Trials/NCT04638790
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
Is NCT04638790 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for hodgkin lymphoma, adult.
Treatment: Doxorubicin · Bleomycin · Vinblastine · Dacarbazine · Etoposide · Doxorubicin · Cyclophosphamide · Vincristine · Dexamethasone · Dacarbazine — The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
absolute neutrophil count >1,0 x109/L, platelets >75 x109/L
Kidney function
Creatinine within normal institutional limits or creatinine clearance >50 mL/min/1.73 m2
Liver function
Total bilirubin <2 mg/dl without a pattern consistent with Gilbert's syndrome
Cardiac function
Cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular hypertrophy or LVEF ≤50% at echocardiography. Abnormal QTc interval prolonged (>450 msec in males; >470 msec in women)
Adequate organ and marrow function as defined below: absolute neutrophil count >1,0 x109/L, platelets >75 x109/L; Total bilirubin <2 mg/dl without a pattern consistent with Gilbert's syndrome; Creatinine within normal institutional limits or creatinine clearance >50 mL/min/1.73 m2; Cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular hypertrophy or LVEF ≤50% at echocardiography. Abnormal QTc interval prolonged (>450 msec in males; >470 msec in women)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04638790 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 50 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages